Literature DB >> 31871222

Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers.

Ronald A Lubet1, Brandy M Heckman-Stoddard2, Jennifer T Fox3, Fariba Moeinpour4, M Margaret Juliana4, Robert H Shoemaker3, Clinton J Grubbs4.   

Abstract

In both estrogen receptor/progesterone receptor-positive (ER+/PR+) human breast cancer and in ER+/PR+ cancers in the methylnitrosourea (MNU)-induced rat model, short-term modulation of proliferation in early cancers predicts preventive/therapeutic efficacy. We determined the effects of known effective/ineffective chemopreventive agents on proliferative index (PI) in both rat mammary epithelium and small cancers. Female Sprague-Dawley rats were treated with MNU at 50 days of age. Five days later, the rats were treated with the individual compounds for a period of 14 days. At that time, normal mammary tissue from the inguinal gland area was surgically removed. After removal, the rats remained on the agents for an additional 5 months. This cancer prevention study confirmed our prior results of striking efficacy with tamoxifen, vorozole, Targretin, and gefitinib, and no efficacy with metformin, naproxen, and Lipitor. Employing a separate group of rats, the effects of short-term (7 days) drug exposure on small palpable cancers were examined. The PI in both small mammary cancers and in normal epithelium from control rats was >12%. In agreement with the cancer multiplicity data, tamoxifen, vorozole, gefitinib, and Targretin all strongly inhibited proliferation (>65%; P < 0.025) in the normal mammary epithelium. The ineffective agents metformin, naproxen, and Lipitor minimally affected PI. In the small cancers, tamoxifen, vorozole, and Targretin all reduced the PI, while metformin and Lipitor failed to do so. Thus, short-term changes in the PI in either normal mammary epithelium or small cancers correlated with long-term preventive efficacy in the MNU-induced rat model. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31871222      PMCID: PMC7060128          DOI: 10.1158/1940-6207.CAPR-19-0318

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  26 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

Authors:  Mitch Dowsett; Ian E Smith; Steve R Ebbs; J Michael Dixon; Anthony Skene; Clive Griffith; Irene Boeddinghaus; Janine Salter; Simone Detre; Margaret Hills; Susan Ashley; Stephen Francis; Geraldine Walsh
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

3.  Early Surrogate Markers of Treatment Activity: Where Are We Now?

Authors:  Marie Klintman; Mitchell Dowsett
Journal:  J Natl Cancer Inst Monogr       Date:  2015-05

4.  Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.

Authors:  Sirwan M Hadad; Philip Coates; Lee B Jordan; Ryan J O Dowling; Martin C Chang; Susan J Done; Colin A Purdie; Pamela J Goodwin; Vuk Stambolic; Stacy Moulder-Thompson; Alastair M Thompson
Journal:  Breast Cancer Res Treat       Date:  2015-02-15       Impact factor: 4.872

5.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Authors:  Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

6.  Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.

Authors:  Konstantin Christov; Clinton J Grubbs; Anne Shilkaitis; M Margaret Juliana; Ronald A Lubet
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 7.  Models for early chemoprevention trials in breast cancer.

Authors:  C J Fabian; B F Kimler; R M Elledge; W E Grizzle; S W Beenken; J H Ward
Journal:  Hematol Oncol Clin North Am       Date:  1998-10       Impact factor: 3.722

8.  Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.

Authors:  Yan Lu; Ming You; Zara Ghazoui; Pengyuan Liu; Peter T Vedell; Weidong Wen; Ann M Bode; Clinton J Grubbs; Ronald A Lubet
Journal:  Cancer Prev Res (Phila)       Date:  2013-09-25

9.  Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.

Authors:  R A Lubet; V E Steele; R DeCoster; C Bowden; M You; M M Juliana; I Eto; G J Kelloff; C J Grubbs
Journal:  Carcinogenesis       Date:  1998-08       Impact factor: 4.944

Review 10.  Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression.

Authors:  Ronald A Lubet; Vernon E Steele; Robert H Shoemaker; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2018-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.